Skip to main
BSX
BSX logo

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific has demonstrated significant sales growth across various product lines, with the Watchman device experiencing a 35% year-over-year increase due to strong uptake in concomitant procedures, while the electrophysiology (EP) segment surged by 63%, highlighting successful market share gains. The company is projecting robust organic sales growth of 11-13% for the fourth quarter, alongside expected GAAP EPS in the range of $0.48 to $0.52, underscoring a positive financial outlook. Additionally, promising future revenue streams are anticipated from the Nalu device, expected to surpass $60 million in sales by 2025 and grow at an annual rate exceeding 25% in 2026, further supporting a favorable long-term performance perspective.

Bears say

Boston Scientific faces a challenging outlook primarily due to anticipated foreign exchange headwinds of approximately $0.04 per share, which could impede full-year adjusted earnings. The company's reliance on its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) segments, which operate in mature markets characterized by pricing pressures, may hinder future revenue growth prospects, particularly if there are delays in new product launches. Furthermore, the firm's recent performance highlights mixed growth across various segments, with a significant underperformance in Urology and potential integration issues that could adversely affect operational efficiency and market expectations.

Boston Scientific (BSX) has been analyzed by 19 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 19 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $124.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $124.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.